OWL Bio to Develop Obesity Treatment Reducing Annual Doses from 52 to 4
OWL Bio, a company specializing in long-acting injectable drugs, is accelerating the development of next-generation obesity treatments after being consecutively selected for government-funded projects by the Ministry of Health and Welfare, followed by the Ministry of Trade, Industry, and Energy.
On the 16th, when Novo Nordisk, a global pharmaceutical company, launched its obesity treatment drug "Wegovy" in South Korea, a notice saying "Wegovy Stocked" was posted at a pharmacy in Jongno-gu, Seoul. Photo by Jinhyung Kang aymsdream@
View original imageOn August 6, OWL Bio announced that it has been finally selected for the R&D-linked national project on materials and components technology development, supervised by the Ministry of Trade, Industry, and Energy.
The goal of this project is to develop an ultra-long-acting microsphere drug delivery platform-based GLP-1 RA obesity treatment formulation and to enter Phase 1 clinical trials. The research, which began last month, will continue through December 2028, with a total R&D budget of 3.4 billion won.
Through this project, OWL Bio plans to develop an ultra-long-acting semaglutide formulation (AUL018) that maintains its therapeutic effect for three months with a single administration and to secure approval for a global Phase 1 clinical trial plan. The objective is to reduce the administration frequency for GLP-1-based obesity treatments from 52 times per year to 4 times per year.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Aram Kim, research director at OWL Bio, stated, "Based on the secured government funding, we will successfully complete the Phase 1 clinical entry and demonstrate unprecedented technological competitiveness in the global obesity treatment market."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.